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Omphalomesenteric duct remnant 
adenocarcinoma in adults: a case study
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Abstract 
Introduction: The omphalomesenteric duct (OMD) or the vitelline duct (VD) is the embryonic structure connecting 
the vitelline sac to the primitive gut. It undergoes obliteration at 5–9 weeks of gestation. Failure of this duct to close, 
which occurs in approximately 2% of the population, can lead to various types of VD residual diseases. A persistent 
OMD remnant is pathological, and it typically presents in the pediatric population. Meckel diverticulum is the most 
common anomaly that results from failure of resorption of the OMD. In extremely rare instances, OMD remnant 
adenocarcinomas have been reported in the adult population.
Case description: In this study, we present a case of OMD remnant adenocarcinoma with axillary lymph node 
metastases in an adult male.
Discussion and Evaluation: Because OMD remnant adenocarcinoma is rare, few relevant studies have been 
reported. The final diagnosis of navel VD residual adenocarcinoma depends on postoperative pathology and immu-
nohistochemical analysis. The follow-up treatment in OMD is similar to the chemotherapy regimens of postoperative 
gastrointestinal malignant tumors.
Conclusions: In this report, the patient experienced no complications after surgery and was discharged on the 
seventh postoperative day, followed by 12 courses of postoperative FOLFOX6 scheme chemotherapy. By the end of 
chemotherapy, the patient had no evidence of recurrent disease and metastasis across the reexamination of PET–CT.
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Background
The omphalomesenteric duct (OMD) or the vitelline 
duct (VD) is the embryonic structure connecting the 
vitelline sac to the primitive gut, which undergoes oblit-
eration at five to nine weeks of gestation (Bagade and 
Khanna 2015). Failure of this duct to close, which occurs 
in approximately 2% of the population, can produce vari-
ous types of residual VD disease (Levy and Hobbs 2004). 
Meckel’s diverticulum is the most common congenital 
abnormality of residual VD disease (Khati et  al. 1998), 
which is usually diagnosed in the pediatric population. 
Although a few reports have described OMD remnants 
in the adult population, to date, there are no reports on 
cancerous OMD remnants. We present the case of a 
56-year-old male patient with an OMD remnant adeno-
carcinoma and axillary lymph node metastasis.
Case presentation
A 56-year-old male presented to our hospital in June 2015 
with a 1-month history of an axillary lump. Preoperative 
pathological examination confirmed it as a metastatic 
adenocarcinoma through regional lymph node resec-
tion (Fig.  1). The patient denied any pain, fevers, chills, 
or any significant weight loss. The patient had no fam-
ily history of cancer or hereditary intestinal disorders. 
Physical examination revealed a hard, mobile, 3 ×  2  cm 
lesion with unclear border and a smooth surface, which 
was palpable at the position beneath the umbilicus. Clini-
cal examination results for the respiratory, cardiovas-
cular, gastrointestinal, and nervous systems and routine 
laboratory examination results were normal. Some tumor 
markers were slightly higher than the marginal values 
Open Access
*Correspondence:  moxianwei3@126.com 
Department of Gastrointestinal Surgery, Affiliated Tumor Hospital 
of Guangxi Medical University, 71 Hedi Road, Nanning 530021, Guangxi 
Autonomous Region, China
Page 2 of 4Zhou et al. SpringerPlus  (2016) 5:2027 
(CEA: 10.02 ng/mL, normal range: 0–6.5 ng/mL; CA72-
4: 17.12 U/mL, normal range: 0–6.7 U/mL). A computed 
tomography (CT) scan of the abdomen confirmed the 
mass under the umbilicus, but it was difficult to differen-
tiate it from the intestine. The soft tissue density around 
the mass was increased. The lesion measured approxi-
mately 2.8 ×  2.0  cm (Fig.  2). Several lymph nodes were 
palpable in the right axillary area (Fig. 3). The 18F-fluoro-
deoxyglucose (18F-FDG) positron emission tomography–
computed tomography (PET–CT) scan of the umbilicus 
mass revealed a focally increased metabolic rate, and 
there was no clear border line with adjacent bowel loops 
(Fig. 4). There was no significant uptake in the right abdo-
men. Increased metabolic rate was also found on the right 
side of axillary lymph nodes (Fig. 5), which may have been 
caused by postoperative inflammation. No other areas of 
increased metabolic uptake were identified.
Based on the preoperative evaluation, we first performed 
a laparoscopic exploration to exclude other diseases. Then, 
open surgery was performed to remove the bellybutton 
neoplasm and urachus. Postoperative pathological exami-
nation confirmed that the specimen from the transected 
umbilicus and urachus tissue was moderately differenti-
ated adenocarcinoma (Fig.  6). Immunohistochemistry 
analysis results were as follows: CK7(+), CK20(+), Vil-
lin(+), CDX-2(±), MUC2(+), MUC5A(+), MUC6(−), 
Fig. 1 a, b Histopathological examination of the lymph nodes in 
the right axillary region. Hematoxylin and eosin stain (H & E stain), 
40× magnification
Fig. 2 Abdominal CT scan: umbilicus lump (arrow), which was sus-
pected to be an umbilicus tumor
Fig. 3 CT scan: postoperative changes of lymph nodes in the right 
axillary area (arrow). The density of soft tissue around this structure 
was increased
Fig. 4 The PET–CT scan: umbilicus lump (arrow). An increased meta-
bolic rate was revealed. Radioactive tracer: 18F-FDG
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TTF-1(−), PSA(−), PAX8(−), and GATA-3(−). The 
patient experienced no complications after surgery and 
was discharged on the seventh postoperative day. After 12 
courses of postoperative FOLFOX6 scheme chemother-
apy, the patient had no evidence of recurrent disease or 
metastasis across the reexamination of PET–CT.
Discussion
Congenital gastrointestinal malformations comprise 
approximately 6% of all congenital anomalies (Yah-
chouchy et al. 2001). VD remnants are some of the most 
common congenital gastrointestinal anomalies and result 
in several other anomalies, including omphalomesenteric 
fistulas, enterocysts, fibrous bands connecting the intes-
tine to the umbilicus, and Meckel’s diverticulum (Uppal 
et al. 2011). Nevertheless, Meckel’s diverticulum accounts 
for 90% of all VD anomalies. It occurs more frequently 
in males, and in the majority of cases, it is asymptomatic 
and only incidentally discovered during laparotomies con-
ducted for other reasons, either through imaging or lapa-
roscopy (Park et  al. 2005; Bani-hani and Shatnawi 2004; 
Matsagas et al. 1995; Pinero et al. 2002; Sinha 2005).
Vitelline duct is seen most often in neonates and infants 
(Kamii et al. 1992). Very few cases have been reported in 
adults. In this report, we present the case of a 56-year-
old male with asymptomatic OMD remnants with axil-
lary masses. However, pathological examination proved 
that these were both metastatic adenocarcinoma. The 
pathogenesis of residual VD adenocarcinoma is not 
yet clear; gland metaplasia in residual gastrointestinal 
mucosal epithelia may be the foundation of the patho-
genesis of residual VD adenocarcinoma. Axillary lymph 
node metastasis was probably associated with the super-
ficial shallow lymph circumfluence of the abdominal wall 
in this patient’s case. Above the navel, the superficial vein 
drained into the axillary vein via the thoracic abdominal 
veins, accompanied by corresponding vein lines of lym-
phatic backflow into the axillary lymph nodes; below the 
umbilicus, lymph circumfluence was present in the shal-
low inguinal lymph nodes. We reviewed the literature, 
but no similar cases were found. Thus, we believe that this 
may be the first report of an OMD remnant adenocarci-
noma with axillary lymph node metastasis in an adult.
The correct diagnosis of an OMD remnant before sur-
gery is often difficult because an OMD remnant simu-
lates many other abdominal pathologies. Differential 
diagnoses include Crohn’s disease, colonic diverticulitis, 
perforated neoplasms, pelvic inflammatory disease and 
urachal remnants (when localized to the periumbilical 
region) (Salemis 2009). A previous study presented diag-
nostic modalities that are used in the investigation of 
patients with suspected OMD remnants (Ioannidis et al. 
2012). The case we report here had no typical sympto-
matic VD remnants. PET–CT is valuable for the diag-
nosis of gastrointestinal tumors. Combined PET–CT 
scanners have been introduced into clinical practice to 
provide additional information about tumors (Antoch 
et al. 2003). In this case, the PET–CT was the foundation 
of the diagnosis of the VD tumor.
Fig. 5 The PET–CT scan: axillary lymph nodes (arrow). Radioactive 
tracer: 18F-FDG
Fig. 6 Representative images of the postoperative pathological examination of the umbilicus. H & E stain, a 100× magnification; b 400× magnifi-
cation
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In the present case, OMD remnant adenocarcinoma 
was suspected from the physical and imaging examina-
tion findings. Surgery provided a definitive diagnosis of 
an OMD remnant and curative treatment by resection 
with minimal invasion (Morita et al. 2015). Importantly, 
this procedure provided both a good field of view around 
the umbilicus and an adequate working space in which to 
definitively diagnose the OMD remnant. Although it is a 
rare clinical entity, a complicated OMD remnant should 
always be kept in mind in patients presenting with an 
umbilical mass.
Omphalomesenteric duct remnant adenocarcinoma is 
very rare, and few relevant studies have been reported. 
The combined pathological type, operation findings, 
imaging findings and even a colonoscopy are needed for 
diagnosis. Final diagnosis of the navel VD residual adeno-
carcinoma is made on the basis of postoperative patho-
logical and immunohistochemical results; follow-up 
treatment should choose one type of chemotherapy regi-
men of postoperative gastrointestinal malignant tumors.
Patients with axillary lymph node metastases require 
adjuvant chemotherapy 6  months after resection of the 
primary tumors (Des Guetz et  al. 2010). This therapy 
might include FOLFOX (Maindrault-goebel et al. 2000), 
CapeOX (Schmoll et  al. 2007), or FLOX (Kuebler et  al. 
2007). For patients who cannot use oxaliplatin, the sin-
gle drug capecitabine (Twelves et  al. 2005) or 5-FU/LV 
(Haller et  al. 2005) can be used. FOLFOX is among the 
most effective regimens for treating resistant gastrointes-
tinal cancer (Maindrault-goebel et  al. 2000). FOLFOX6 
chemotherapy was administered to this patient. A clinical 
review of this patient’s treatment revealed an ideal cura-
tive effect and no signs of recurrence or metastasis.
Conclusion
We have presented an extremely rare case of OMD rem-
nant adenocarcinoma safely resected by surgery in an 
adult patient. Imaging plays a critical role in the diagnosis 
of OMD remnants. An awareness of the variety of these 
anomalies is essential to their proper management.
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